Cited by 61Treatment of Major DepressionPsychological Treatments and DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

A critical review of pharmacotherapy for major depressive disorder.

Open access
Dupuy, Jamie M., Ostacher, Michael J., Huffman, Jeffrey, Perlis, Roy H., Nierenberg, Andrew A.·2011·The International Journal of Neuropsychopharmacology

Abstract

Newer generation antidepressant drugs, with improvements in safety and tolerability, have replaced tricyclic antidepressants as first-line treatment of depressive illness. However, no single antidepressant drug from any class has distinguished itself as the obvious first-line treatment of major depression. The choice of therapy is driven primarily by patient choice, with informed consent for the risks of adverse effects. Cost has become an additional factor in this decision as several of the newer antidepressant drugs are now available in generic form. Several augmentation and drug-switching strategies have demonstrated benefit in refractory illness. While no single strategy distinguished itself as superior to the others, some have been more rigorously tested. Ongoing efforts at improving effectiveness, time to response, and tolerability have led to novel drug therapies. Efforts at characterizing predictors of treatment outcomes now include pharmacogenetic studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145711000083

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A.
Affiliations
  • Harvard University (US)
  • Stanford Medicine (US)
Corresponding author
Dupuy, Jamie M.
Venue
The International Journal of Neuropsychopharmacology
Published
2011-02-24
Volume
14
Issue
10
Pages
1417-1431
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2168253623
Cited by
61
References
102
Citations by year
2025: 1 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 12 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 4 · 2014: 4 · 2013: 4 · 2012: 5
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • GlaxoSmithKline
  • Harvard University (UL1RR025758)
  • Harvard Catalyst (UL1-RR025758)
  • National Institutes of Health
  • National Institute on Alcohol Abuse and Alcoholism (K23AA016340)
  • National Center for Research Resources (UL1RR025758, RR025758)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
major depressive disorder, antidepressants, pharmacotherapy, tricyclic antidepressants, first-line therapy, treatment-resistant depression, augmentation strategies, drug switching, adverse effects, cost, newer antidepressants, pharmacogenetics, predictors of treatment outcome
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Drug Resistance, Drug Therapy, Combination, Humans, Pharmacogenetics, Drug Costs, Drugs, Generic, Treatment Outcome, Practice Guidelines as Topic, Risk Assessment, Patient Selection, Evidence-Based Medicine, Drug Substitution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review